DNMT1 and neoplasm: Recently, the novel small molecule CM-272, which co-targets G9a and DNMT1, developed in our Institution, has been tested in hematologic tumors, hepatocellular carcinoma and bladder cancer models [14–16] This double-targeting agent has been highly successful in inhibiting tumor growth in these models both in vitro and in vivo, causing cell proliferation inhibition and triggering cell death.